CAMOU, Fabrice; TINEVEZ, Claire; BEGUET-YACHINE, Mathilde; BELLECAVE, Pantxika; RATIARISON, Diana; TUMIOTTO, Camille; LAFARGE, Xavier; GUISSET, Olivier; MOURISSOUX, Gaelle; LAFON, Marie-Edith; BONNET, Fabrice; ISSA, Nahema

doi:10.1002/jmv.27032

Voir/Ouvrir

MFP_Jmv_2021_Camou.pdf (814.9Ko)

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

CAMOU, Fabrice
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]

TINEVEZ, Claire
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]

BEGUET-YACHINE, Mathilde
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]

Langue

Article de revue

Ce document a été publié dans

Journal of Medical Virology. 2021-05-03p. Online ahead of print

Résumé en anglais

This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID-19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia. A retrospective cohort study was conducted in intensive care unit (ICU). All patients with severe COVID-19 pneumonia for whom RNAemia remained positive more than 14 days after onset of the infection were included and given CPT. The primary objective was to evaluate SARS-CoV-2 RNAemia 7 days (D7) after CPT. A total of 14 patients were included and they received a median CPT volume of 828 ml (range: 817-960). CPT was administered in a median time of 14 days after ICU admission. At D7, 13/14 patients had negative SARS-CoV-2 blood PCR and one patient had negative blood PCR 11 days after CPT. At D7 and at D14, the clinical status was improved in 7/14 and 11/14 patients, respectively. The 28-day mortality rate was 14%. No CPT-related adverse effects had been reported. CPT is safe and may be efficient in patients with protracted RNAemia admitted in ICU for severe COVID-19 pneumonia. Randomized controlled trials are needed to confirm these results.< Réduire

Mots clés en anglais

Combination therapy

Disease control

Generalized infection

Pathogenesis

SARS coronavirus

Virus classification

URI

https://oskar-bordeaux.fr/handle/20.500.12278/182256

DOI

http://dx.doi.org/10.1002/jmv.27032

Voir/Ouvrir

Métadonnées

Licence d’utilisation du document

Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche